Skip to main content

Eculizumab

Volume 481: debated on Monday 27 October 2008

To ask the Secretary of State for Health (1) if he will assist primary care trusts with the funding of eculizumab; and if he will make a statement; (228829)

(2) how many primary care trusts in England and Wales are funding the use of eculizumab in the treatment of paroxysmal nocturnal haemoglobinuria;

(3) which primary care trusts in England and Wales have refused to fund the use of eculizumab in the treatment of paroxysmal nocturnal haemoglobinuria on the grounds of cost-effectiveness.

My right hon. Friend the Minister for Public Health made a written ministerial statement on 8 October 2008, Official Report, columns 16-17WS, setting out the current position for the NHS commissioning of patients with paroxysmal nocturnal haemoglobinuria (PNH). The National Specialised Commissioning team are making good progress with arrangements to ensure that all patients who require the drug eculizumab before the national commissioning starts on 1 April 2009 will receive it.

The National Assembly for Wales will look at the position for PNH patients in Wales.